Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma.

Ladomersky E, Zhai L, Lenzen A, Lauing KL, Qian J, Scholtens DM, Gritsina G, Sun X, Liu Y, Yu F, Gong W, Liu Y, Jiang B, Tang T, Patel R, Platanias LC, James CD, Stupp R, Lukas RV, Binder DC, Wainwright DA.

Clin Cancer Res. 2018 Jun 1;24(11):2559-2573. doi: 10.1158/1078-0432.CCR-17-3573. Epub 2018 Mar 2.

PMID:
29500275
2.

Impact of immunotherapy among patients with melanoma brain metastases managed with radiotherapy.

Stokes WA, Binder DC, Jones BL, Oweida AJ, Liu AK, Rusthoven CG, Karam SD.

J Neuroimmunol. 2017 Dec 15;313:118-122. doi: 10.1016/j.jneuroim.2017.10.006. Epub 2017 Oct 13.

PMID:
29153603
3.

Infiltrating T Cells Increase IDO1 Expression in Glioblastoma and Contribute to Decreased Patient Survival.

Zhai L, Ladomersky E, Lauing KL, Wu M, Genet M, Gritsina G, Győrffy B, Brastianos PK, Binder DC, Sosman JA, Giles FJ, James CD, Horbinski C, Stupp R, Wainwright DA.

Clin Cancer Res. 2017 Nov 1;23(21):6650-6660. doi: 10.1158/1078-0432.CCR-17-0120. Epub 2017 Jul 27.

PMID:
28751450
4.

The Boosting Potential of Bacteria in Cancer Immunotherapy.

Binder DC, Wainwright DA.

Trends Mol Med. 2017 Jul;23(7):580-582. doi: 10.1016/j.molmed.2017.05.008. Epub 2017 Jun 2.

5.

Non-tumor cell IDO1 predominantly contributes to enzyme activity and response to CTLA-4/PD-L1 inhibition in mouse glioblastoma.

Zhai L, Ladomersky E, Dostal CR, Lauing KL, Swoap K, Billingham LK, Gritsina G, Wu M, McCusker RH, Binder DC, Wainwright DA.

Brain Behav Immun. 2017 May;62:24-29. doi: 10.1016/j.bbi.2017.01.022. Epub 2017 Feb 4.

6.

Improving vaccine efficacy against malignant glioma.

Ladomersky E, Genet M, Zhai L, Gritsina G, Lauing KL, Lulla RR, Fangusaro J, Lenzen A, Kumthekar P, Raizer JJ, Binder DC, James CD, Wainwright DA.

Oncoimmunology. 2016 Jun 10;5(8):e1196311. doi: 10.1080/2162402X.2016.1196311. eCollection 2016 Aug. Review.

7.

Tumor relapse prevented by combining adoptive T cell therapy with Salmonella typhimurium.

Binder DC, Arina A, Wen F, Tu T, Zhao M, Hoffman RM, Wainwright DA, Schreiber H.

Oncoimmunology. 2016 Feb 18;5(6):e1130207. doi: 10.1080/2162402X.2015.1130207. eCollection 2016 Jun.

8.

Immunotherapy for cancer in the central nervous system: Current and future directions.

Binder DC, Davis AA, Wainwright DA.

Oncoimmunology. 2015 Sep 11;5(2):e1082027. eCollection 2016 Feb. Review.

9.

Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy.

Zhai L, Spranger S, Binder DC, Gritsina G, Lauing KL, Giles FJ, Wainwright DA.

Clin Cancer Res. 2015 Dec 15;21(24):5427-33. doi: 10.1158/1078-0432.CCR-15-0420. Epub 2015 Oct 30. Review.

10.

IV Administered Gadodiamide Enters the Lumen of the Prostatic Glands: X-Ray Fluorescence Microscopy Examination of a Mouse Model.

Mustafi D, Gleber SC, Ward J, Dougherty U, Zamora M, Markiewicz E, Binder DC, Antic T, Vogt S, Karczmar GS, Oto A.

AJR Am J Roentgenol. 2015 Sep;205(3):W313-9. doi: 10.2214/AJR.14.14055.

11.

Radiotherapy and immune checkpoint blockade: potential interactions and future directions.

Binder DC, Fu YX, Weichselbaum RR.

Trends Mol Med. 2015 Aug;21(8):463-5. doi: 10.1016/j.molmed.2015.05.007. Epub 2015 Jun 16.

PMID:
26091823
12.

High-affinity peptide-based anticancer vaccination to overcome resistance to immunostimulatory antibodies.

Binder DC, Schreiber H.

Oncoimmunology. 2013 Dec 1;2(12):e26704. Epub 2013 Oct 22.

13.

Antigen-specific bacterial vaccine combined with anti-PD-L1 rescues dysfunctional endogenous T cells to reject long-established cancer.

Binder DC, Engels B, Arina A, Yu P, Slauch JM, Fu YX, Karrison T, Burnette B, Idel C, Zhao M, Hoffman RM, Munn DH, Rowley DA, Schreiber H.

Cancer Immunol Res. 2013 Aug;1(2):123-33. doi: 10.1158/2326-6066.CIR-13-0058.

14.

Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors--letter.

Binder DC, Schreiber H.

Cancer Res. 2014 Jan 15;74(2):632; discussion 635. doi: 10.1158/0008-5472.CAN-13-2216. Epub 2014 Jan 9. No abstract available.

15.

Adoptively transferred immune T cells eradicate established tumors despite cancer-induced immune suppression.

Arina A, Schreiber K, Binder DC, Karrison TG, Liu RB, Schreiber H.

J Immunol. 2014 Feb 1;192(3):1286-93. doi: 10.4049/jimmunol.1202498. Epub 2013 Dec 23.

16.

Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity.

Engels B, Engelhard VH, Sidney J, Sette A, Binder DC, Liu RB, Kranz DM, Meredith SC, Rowley DA, Schreiber H.

Cancer Cell. 2013 Apr 15;23(4):516-26. doi: 10.1016/j.ccr.2013.03.018.

17.

Densely granulated murine NK cells eradicate large solid tumors.

Liu RB, Engels B, Arina A, Schreiber K, Hyjek E, Schietinger A, Binder DC, Butz E, Krausz T, Rowley DA, Jabri B, Schreiber H.

Cancer Res. 2012 Apr 15;72(8):1964-74. doi: 10.1158/0008-5472.CAN-11-3208. Epub 2012 Feb 28.

18.

Cytosolic group IVa phospholipase A2 mediates IL-8/CXCL8-induced transmigration of human polymorphonuclear leukocytes in vitro.

Meliton AY, Muñoz NM, Meliton LN, Binder DC, Osan CM, Zhu X, Dudek SM, Leff AR.

J Inflamm (Lond). 2010 Mar 18;7:14. doi: 10.1186/1476-9255-7-14.

Supplemental Content

Loading ...
Support Center